Chiasma Stock Price, News & Analysis (NASDAQ:CHMA)

$5.68
+0.03 (+0.53 %)
(As of 09/23/2019 06:00 AM ET)
Today's Range
$5.57
Now: $5.68
$5.78
50-Day Range
$4.88
MA: $5.16
$5.71
52-Week Range
$2.11
Now: $5.68
$9.25
Volume500,753 shs
Average Volume323,570 shs
Market Capitalization$238.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHMA
CUSIPN/A
Phone617-928-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.40 per share

Profitability

Net Income$-31,260,000.00

Miscellaneous

Employees18
Market Cap$238.33 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.


Chiasma (NASDAQ:CHMA) Frequently Asked Questions

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.04. View Chiasma's Earnings History.

When is Chiasma's next earnings date?

Chiasma is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Chiasma.

What price target have analysts set for CHMA?

5 Wall Street analysts have issued 12-month target prices for Chiasma's stock. Their forecasts range from $11.00 to $18.00. On average, they expect Chiasma's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 146.5% from the stock's current price. View Analyst Price Targets for Chiasma.

What is the consensus analysts' recommendation for Chiasma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.

Has Chiasma been receiving favorable news coverage?

Media headlines about CHMA stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chiasma earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Chiasma.

Who are some of Chiasma's key competitors?

What other stocks do shareholders of Chiasma own?

Who are Chiasma's key executives?

Chiasma's management team includes the folowing people:
  • Mr. Mark J. Fitzpatrick, Pres, CEO, Sec. & Director (Age 56)
  • Mr. Drew Enamait, VP of Fin. & Admin. and Principal Accounting Officer (Age 45)
  • Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 54)
  • Dr. Gary Patou, Head of Clinical (Age 60)

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Who are Chiasma's major shareholders?

Chiasma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (7.48%), BlackRock Inc. (5.04%), Vanguard Group Inc. (3.31%), Renaissance Technologies LLC (1.30%), Fosun International Ltd (0.39%) and Altshuler Shaham Ltd (0.32%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View Institutional Ownership Trends for Chiasma.

Which major investors are selling Chiasma stock?

CHMA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Chiasma.

Which major investors are buying Chiasma stock?

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Vanguard Group Inc., Renaissance Technologies LLC, Fosun International Ltd, Strs Ohio, Bank of New York Mellon Corp and Charles Schwab Investment Management Inc.. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick and William Ludlam. View Insider Buying and Selling for Chiasma.

How do I buy shares of Chiasma?

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $5.68.

How big of a company is Chiasma?

Chiasma has a market capitalization of $238.33 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.

What is Chiasma's official website?

The official website for Chiasma is http://www.chiasmapharma.com/.

How can I contact Chiasma?

Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]


MarketBeat Community Rating for Chiasma (NASDAQ CHMA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  213 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel